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Administered with Long-Chain Poly(I·C) or the Toll-Like Receptor 4
Agonist Glucopyranosyl Lipid Adjuvant-Stable Emulsion Elicits Potent
Antibody and CD4ⴙ T Cell Immunity and Protection in Mice
Kathrin Kastenmüller,a Diego A. Espinosa,b Lauren Trager,a,f Cristina Stoyanov,a,b Andres M. Salazar,c Santosh Pokalwar,d
Sanjay Singh,d Sheetij Dutta,e Christian F. Ockenhouse,e Fidel Zavala,b Robert A. Sedera
Vaccine Research Center and Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USAa;
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland, USAb; Oncovir,
Washington, DC, USAc; Gennova Biopharmaceuticals Ltd., Pune, Indiad; Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring,
Maryland, USAe; Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, Virginia, USAf

The Plasmodium falciparum circumsporozoite (CS) protein (CSP) is a major vaccine target for preventing malaria infection.
Thus, developing strong and durable antibody and T cell responses against CSP with novel immunogens and potent adjuvants
may improve upon the success of current approaches. Here, we compare four distinct full-length P. falciparum CS proteins expressed in Escherichia coli or Pichia pastoris for their ability to induce immunity and protection in mice when administered
with long-chain poly(I·C) [poly(I·C)LC] as an adjuvant. CS proteins expressed in E. coli induced high-titer antibody responses
against the NANP repeat region and potent CSP-specific CD4ⴙ T cell responses. Moreover, E. coli-derived CS proteins in combination with poly(I·C)LC induced potent multifunctional (interleukin 2-positive [IL-2ⴙ], tumor necrosis factor alpha-positive
[TNF-␣ⴙ], gamma interferon-positive [IFN-␥ⴙ]) CD4ⴙ effector T cell responses in blood, in spleen, and particularly in liver.
Using transgenic Plasmodium berghei expressing the repeat region of P. falciparum CSP [Pb-CS(Pf)], we showed that there was a
1- to 4-log decrease in malaria rRNA in the liver following a high-dose challenge and ⬃50% sterilizing protection with a lowdose challenge compared to control levels. Protection was directly correlated with high-level antibody titers but not CD4ⴙ T cell
responses. Finally, protective immunity was also induced using the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvantstable emulsion (GLA-SE) as the adjuvant, which also correlated with high antibody titers yet CD4ⴙ T cell immunity that was
significantly less potent than that with poly(I·C)LC. Overall, these data suggest that full-length CS proteins and poly(I·C)LC or
GLA-SE offer a simple vaccine formulation to be used alone or in combination with other vaccines for preventing malaria
infection.

M

alaria infection with Plasmodium falciparum causes more
than 600,000 deaths annually as well as significant morbidity
worldwide (1). A range of efforts to control and treat malaria
include public health measures such as insecticide-treated bed
nets, indoor residual spraying, and widespread usage of antimalarial drugs. Despite the impact of these approaches, the most
cost-effective solution to prevent infection and to ultimately control the malaria endemic is to develop a vaccine.
Currently, the most advanced vaccine tested in humans against
P. falciparum infection is RTS,S, which targets the circumsporozoite (CS) protein (CSP), the major and most abundant antigen
expressed on the surfaces of infectious sporozoites. RTS,S given
with the AS01 adjuvant (RTS,S/AS01) shows ⬃30% protection
against clinical disease and severe malaria (2, 3). Thus, while these
first results in phase III trials with RTS,S/AS01 are encouraging,
there may be additional approaches for further optimizing the
breadth, potency, and duration of immunity against the CSP using different immunogens or more-potent adjuvants. In terms of
antigen design, RTS,S is comprised of a truncated form of CSP
containing the central repeat region, NANP, which is a target for
antibody-mediated neutralization, as well as CD8⫹ and CD4⫹ T
cell epitopes at the C-terminal end. This truncated CS protein is
then fused to the hepatitis B virus surface antigen, creating an
immunogenic particle. Therefore, using a more-full-length CSP,
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including the N-terminal end and the R1 region of CSP as well as
the minor repeat region (NVDP), might favor broader antibody
responses than against the NANP repeat region alone (4–8).
Moreover, a full-length CSP may provide additional T cell
epitopes, leading to increased breadth of cellular immunity, which
could also enhance protection. Another approach is to enhance
the humoral and cellular immune responses by altering the type of
adjuvant given with the full-length-CSP-based protein vaccine.
Early studies in mice showed that protection was associated
with high antibody titers (9–11). The next generation of malaria
vaccines combined CSP with more-potent adjuvants, like Pseu-

Received 10 October 2012 Returned for modification 21 November 2012
Accepted 29 November 2012
Published ahead of print 28 December 2012
Editor: J. H. Adams
Address correspondence to Robert A. Seder, rseder@mail.nih.gov.
K.K. and D.A.E. contributed equally to this work.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/IAI.01108-12.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/IAI.01108-12
This article is a U.S. government work, and is not subject to copyright in the United States.

Infection and Immunity

p. 789 – 800

iai.asm.org

789

Kastenmüller et al.

domonas aeruginosa exotoxin A, monophospholipid A (MPL),
mycobacterial cell wall skeleton, or squalene (Detox; Ribi Immunochem) (12–14), which resulted in high antibody titers; however, they failed to confer sufficient protective efficacy (15–17). In
contrast, studies using irradiated sporozoites for vaccination have
shown a critical requirement for gamma interferon (IFN-␥) and
cellular immunity in mediating protection against malaria (18,
19). Accordingly, optimizing CD4⫹ T cell-derived IFN-␥ production after RTS,S vaccination by altering the adjuvant formulation
enhanced protection (20–22). Using the Toll-like receptor 4
(TLR4) ligand MPL and saponin (QS-21) in an oil-water emulsion (AS02) or liposome (AS01B or -E) formulation led to a strong
antibody response and increased CD4⫹ T cell immunity compared to levels induced with older formulations with alum and
MPL (21, 23, 24). Collectively, these data highlight the importance
of adjuvant formulations in optimizing immunity and protection.
In this study, long-chain poly(I·C) [poly(I·C)LC] and the
TLR4 agonist glucopyranosyl lipid adjuvant-stable emulsion
(GLA-SE) were compared as adjuvants when they were administered with a number of CS proteins expressed in the yeast Pichia
pastoris or in Escherichia coli, to which we refer as full length but
which lack the glycosylphosphatidylinositol (GPI) signal region
and contain various numbers of the NANP repeat region.
Poly(I·C)LC is a unique formulation of long-chain doublestranded RNA, polyinosinic-poly(C), and carboxy methylcellulose that has extended in vivo activity compared to that of
poly(I·C). Poly(I·C)LC mediates innate signaling through TLR3
and melanoma differentiation-associated protein 5 (MDA-5),
leading to activation of dendritic cells and induction of interleukin
12 (IL-12) and type I interferons (IFNs) (25–27). In addition,
poly(I·C) has been shown to promote T cell survival and enhance
germinal-center formation through the generation of CD4⫹ T
follicular helper (Tfh) cells (28). As an immune adjuvant,
poly(I·C)LC has been shown to elicit strong humoral and cellular
immunity when administered with a variety of protein- or dendritic cell-targeting vaccines in a number of mouse and nonhuman primate (NHP) studies (29–35).
GLA is a synthetic and therefore homogeneous variant of the
TLR4 agonist lipid A, formulated in a stable oil-in-water emulsion
(SE) (36). Strong Th1 immune responses induced by protein antigens in combination with GLA-SE have been observed in mouse
models of tuberculosis (37), leishmaniasis (38), and influenza
(39). Additionally, GLA-SE showed an adjuvant activity similar to
or enhanced relative to that of MPL-SE (one of the adjuvant components in AS01) in various animal models, such as mice, guinea
pigs, and nonhuman primates (40, 41).
Here, we compare four full-length P. falciparum CS proteins
expressed in E. coli or in the yeast P. pastoris given with
poly(I·C)LC or GLA-SE as an adjuvant and determine their relative immunogenicities and levels of protection using an in vivo
mouse challenge model. Furthermore, one of the CS proteins and
poly(I·C)LC was tested in NHPs. Together, these data provide a
potential simple vaccine formulation for inducing potent and
protective P. falciparum CSP responses.
MATERIALS AND METHODS
Animals. Six- to 8-week-old C57BL/6 mice were obtained from The Jackson Laboratories (Bar Harbor, ME) and maintained in the Vaccine Research Center Animal Care Facility (Bethesda, MD) under pathogen-free
conditions. Male, Indian rhesus macaques were stratified into comparable
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groups on the basis of age and weight. The animals were housed at the
School of Medicine, Comparative Medicine and Veterinary Resources,
University of Maryland. All experiments were conducted according to the
guidelines of the National Research Council under protocols approved by
the Institutional Animal Care and Use Committee at the National Institutes of Health.
Reagents. Four P. falciparum CS proteins were provided by the PATH
Malaria Vaccine Initiative (MVI; Washington, DC) and provided to us in
a blind manner (they were designated CSP1, CSP2, CSP3, and CSP4).
These four proteins are called full length in the text, but they lack the GPI
signal region and contain various numbers of the repeat region. After the
immune studies were completed, it was revealed to us that two proteins
were expressed in E. coli (CSP1 and CSP2) and two were expressed in P.
pastoris (CSP3 and CSP4). CSP1 and CSP2 were provided to the MVI
from Gennova (Pune, India) and WRAIR (Silver Spring, MD), respectively. Protein concentration was measured using a bicinchoninic acid
(BCA) protein assay (Pierce, Rockford, IL). Endotoxin contaminants
were determined using the Limulus amebocyte lysate (LAL) assay (Lonza,
Walkersville, MD). If endotoxin levels exceeded 2 endotoxin units (EU)/
ml, endotoxin was removed by two-phase extraction with Triton X-114.
Small amounts of endotoxin was detected in the E. coli-derived proteins.
Thus, all four proteins, including the two expressed in yeast, which had no
detectable endotoxin, were treated with Triton X-114. All proteins used
for immunization had final endotoxin levels below 1 EU/ml. After removal of endotoxin, protein concentration was determined to confirm
that all groups of mice received the same amount of protein. P. falciparum
CSP15-mer peptides overlapping by 11 amino acids (aa) and spanning the
entire length of the protein (P. falciparum 3D7 strain) were synthesized by
GenScript. Each batch of CSP was tested for accurate size using SDSPAGE.
Antibodies. The following anti-mouse antibodies for flow cytometry
were purchased from BD Pharmingen: purified anti-CD28 (37.51),
PerCP–Cy55–anti-CD3 (145-2C11), and Alexa 700 –anti-CD4 (RM4-5).
The following antibodies were purchased from BioLegend: allophycocyanin (APC)–Cy7–anti-CD8 (53-6.7). LIVE/DEAD fixable violet dead cell
stain (ViViD) were purchased from Molecular Probes, and staining was
performed as described by Perfetto et al. (42). Intracellular staining was
performed according to the BD Cytofix/Cytoperm kit instructions using
APC–anti-IFN-␥ (XMG1.2), phycoerythrin (PE)–Cy7–anti-tumor necrosis factor alpha (anti-TNF-␣) (MP6-XT22), and PE–anti-IL-2 (MQ117H12), which were purchased from BD Biosciences, and Alexa Fluor
488 –anti-IL-10 (JES5-16E3), which was purchased from eBioscience.
For staining of nonhuman primate (NHP) cells, the following antihuman antibodies were purchased from BD Pharmingen: purified antiCD49d (9F10), APC–Cy7–anti-CD3 (SP34-2), PE–Cy7–anti-TNF-␣
(MAb11), PE–anti-IL-2 (MQ1-17H12), PE–Cy5–anti-CD95 (DX2), and
fluorescein isothiocyanate (FITC)–anti-IFN-␥ (B27). PacificBlue–antiCCR7 (TG8/CCR7) was purchased from BioLegend. Anti-CD45RA–R
phycoerythrin-Texas Red (ECD) (clone 2H4LDH11LDB9) was purchased from Beckman Coulter, and Qdot605–anti-CD4 (S3.5) was purchased from Invitrogen. The conjugates Alexa 680 –anti-CD28 (CD28.2)
and Qdot655–anti-CD8 (RPA-T8) were produced in-house by the laboratory of Mario Roederer (NIAID, NIH, Bethesda, MD).
Immunizations. C57BL/6 mice were immunized with 2 g or 20 g of
CSP, with or without 50 g poly(I·C)LC (Oncovir, Inc., Washington, DC)
or 5 g GLA-SE (Infectious Disease Research Institute, Seattle, WA)
which are the optimal doses for these adjuvants. Naive mice or mice immunized with the adjuvant alone served as controls. The vaccines were
administered subcutaneously (s.c.) in both hind footpads in a total volume of 50 l per foot. Animals were immunized at weeks 0 and 3 or 0, 3,
and 6.
Rhesus macaques were immunized with 100 g of P. falciparum CSP
mixed with 1 mg of poly(I·C)LC. A total volume of 1 ml was injected s.c.
into the deltoid area of the upper arm. For boosting, the opposite arm was
used. Animals were immunized at weeks 0, 5, and 16.
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FIG 1 Graphic diagrams of the characteristics of four different CSPs. Full-length CSP consists of the signal peptide (SP), two highly conserved motifs at the Nand C-terminal ends of the protein, region 1 and region 2 plus (R1 and R2), tandem repeats (37 NANP repeats), and the GPI anchor signal (GPI). CSP1 and CSP2
were produced by expression in Escherichia coli, CSP3 and CSP4 by expression in P. pastoris.

Analysis of CD4ⴙ T cell responses. Cells from mice were harvested
from spleens at various times postvaccination, and single-cell suspensions
(2 ⫻ 106 cells/well) from individual mice were incubated for 5 h with
anti-CD28, 10 g/ml Brefeldin A, and 2 g/ml CSP peptide pool. Cells
were stained with the viability dye LIVE/DEAD fixable violet dead cell
stain (ViViD), CD4, and CD8, followed by intracellular staining for CD3,
IFN-␥, IL-2, IL-10, and TNF-␣ using the BD Cytofix/Cytoperm kit according to the manufacturer’s instructions. For intrahepatic-lymphocyte
isolation, the liver was perfused with phosphate-buffered saline (PBS)
before being processed, and lymphocytes were isolated by Percoll density
centrifugation. Stimulation and staining were performed as described for
splenocytes in this section.
For analysis of NHP peripheral blood mononuclear cells (PBMCs),
cryopreserved cells were thawed and rested overnight at 37°C. The next
day, cells (2 ⫻ 106 cells/well) were stimulated for 5 h with anti-CD49d and
anti-CD28, 10 g/ml Brefeldin A, and 2 g/ml CSP peptide pool. Cells
were stained in warm medium with CCR7, followed by surface staining
with a LIVE/DEAD fixable aqua dead cell stain kit (Invitrogen), CD45RA,
CD95, CD4, and CD8 in PBS. Intracellular cytokine staining was performed using IFN-␥, IL-2, CD3, and TNF-␣ with the BD Cytofix/Cytoperm kit according to the manufacturer’s instructions. Cells were resuspended in 1% paraformaldehyde, acquired on a modified BD LSR II flow
cytometer, and analyzed using FlowJo software (Tree Star), Pestle, and
SPICE (Mario Roederer, NIAID, NIH).
Detection of CSP-specific antibodies. Serum samples from immunized mice and NHPs were analyzed for IgG antibodies specific for the
repeat region ([NANP]6 peptide) of P. falciparum CSP by the Malaria
Serology Laboratory at WRAIR. Plates were read at 414 nm, and endpoint
titers were calculated at an optical density (OD) of 1.0. For analysis of total
CSP-specific IgG1 and IgG2a titers, enzyme-linked immunosorbent assay
(ELISA) plates were coated with CSP1 protein at a concentration of 1
g/ml and washed. Serially diluted serum samples from immunized or
control mice were added in duplicate for 2 h. After being washed, samples
were incubated with either anti-mouse IgG1-horseradish peroxidase
(HRP) or anti-mouse IgG2a-HRP. Plates were then developed with
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3,3=,5,5=-tetramethylbenzidine substrate-chromogen (Dako) and read at
450 nm. Midpoint 50% effective concentration (EC50) titers were calculated using 4PL curve fitting.
Immunofluorescent antibody (IFA) assay. To determine whether serum bound to sporozoites, slides (Tekdon Inc.; poly-L-lysine coated) were
coated with a 10-l suspension of sporozoites of P. berghei expressing the
repeat region of CSP from P. falciparum [Pb-CS(Pf)] at a concentration of
4 ⫻ 105 to 6 ⫻ 105 sporozoites/ml and air dried. Serum samples from
immunized mice or NHPs were diluted in PBS-1% bovine serum albumin
(BSA) prior to their addition to the slides (10 l of sample) and then
incubated for 30 min at room temperature. Slides were then washed with
PBS-1% BSA, and 10 l of a secondary-antibody solution [Alexa Fluor
488 F(ab=)2 fragment of goat anti-mouse IgG(H⫹L) (2 g/ml; Invitrogen) and FITC-labeled goat anti-monkey IgG(H⫹L) (KPL) for mice and
NHPs, respectively] was added for 30 min at room temperature; then
slides were washed with PBS-1% BSA. Fluorescent sporozoites were visualized using an upright fluorescence microscope (Nikon Eclipse 90i). The
lowest titer at which sporozoites were visualized was scored as positive.
Binding of serum antibodies to sporozoites was scored as ⫹⫹⫹ (very
good), ⫹⫹ (good), ⫹ (weak), or ⫺ (no) binding.
Sporozoite challenge. Mice were challenged intravenously (i.v.) with
1.5 ⫻ 104 transgenic Pb-CS(Pf) sporozoites, kindly provided by E. Nardin
(10). Approximately 40 h later, mice were euthanized to assess parasite
burden in livers. Parasite loads were determined by quantitative PCR
(qPCR) for P. berghei 18S rRNA (43). For the assessment of blood-stage
parasitemia, mice were challenged i.v. with 1 ⫻ 103 of the transgenic
Pb-CS(Pf) sporozoites. Starting on day 4, blood smears were taken and
observed under a microscope. Smears were fixed with methanol (for 30 s)
before being stained with a 10% Giemsa stain solution (Sigma-Aldrich)
for 15 min.
Serum transfer. Serum was collected from individual mice 2 weeks
after three immunizations with 20 g CSP1 and poly(I·C)LC, and 0.5 ml
was transferred i.v. immediately prior to challenge.
Isolation of PBMCs from NHPs. PBMCs were isolated from fresh
blood by Ficoll density centrifugation using LeucoSep tubes (Greiner Bio
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FIG 2 C57BL/6 mice (n ⫽ 4) were immunized twice, 3 weeks apart, with either 2 g or 20 g of various CSPs and 50 g poly(I·C)LC. Naive mice and mice that

received poly(I·C)LC alone or 20 g of each protein alone served as controls. Four weeks later, T cells in spleens were analyzed for cytokine production by flow
cytometry. Frequencies of CSP-specific IFN-␥-, IL-2-, TNF-␣-, or IL-10-producing CD4⫹ T cells are shown for protein-only and control mice (A) and mice that
received either 2 g (B) or 20 g (C) of CSP with poly(I·C)LC. Data are expressed as means ⫹ SD and are representative of two independent experiments. *, P ⬍
0.05. The color of the asterisk indicates the group to which the value is being compared.

One) according to the manufacturer’s instructions. After several washes,
cells were cryopreserved.
Statistics. The majority of the data and statistical analysis were created
using Prism software (GraphPad) and a Mann-Whitney test. Differences
were found to be significant when P was less than 0.05 or 0.01. Data are
represented as means ⫹ standard deviations (SD) or as geometrical
means, as indicated in the figure legends. Bar and pie charts of cytokine
production were created using FlowJo software (Tree Star), Pestle, and
SPICE (Mario Roederer, NIAID, NIH).

RESULTS

E. coli-derived CSP induces robust CD4ⴙ T cell cytokine responses. The goal of this blinded study was to compare the immunogenicities of four full-length CSPs (CSP1 to -4) in combination with different adjuvants. CSP1 and CSP2 were produced in E.
coli, while CSP3 and CSP4 were expressed in the yeast P. pastoris.
The amino acid sequences of CSP2 and CSP3, derived from the
3D7 strain of the malaria parasite, share strong homology at the
amino- and carboxy-terminal regions but differ in their numbers
of NANP repeats (Fig. 1). CSP1 and CSP4 are derived from the
India strain IND637HDD1, contain all 37 NANP repeats, and
share strong amino acid sequence homology. The 3D7 strain has a
deletion in the N-terminal region (aa 91 to 97), whereas this region is intact in the India strain. We first selected poly(I·C)LC as
an adjuvant based on its potency for generating T cell and antibody responses shown in prior studies by our lab and others (34,
35). C57BL/6 mice were immunized twice, 3 weeks apart, with 2
g or 20 g of CSP with or without 50 g poly(I·C)LC. Four
weeks after the second immunization, CD4⫹ T cell responses in
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FIG 3 C57BL/6 mice (n ⫽ 4) were immunized as described in the legend of
Fig. 2. At the time of tissue harvest, sera were collected and analyzed for CSPspecific IgG antibodies in protein-only and control mice (A) and mice that
received either 2 g (B) or 20 g (C) of CSP with poly(I·C)LC. Antibodies were
measured against part of the repeat region ([NANP]6). Data points are
graphed as geometrical means of endpoint titers and are representative of two
independent experiments. *, P ⬍ 0.05. The color of the asterisk indicates the
group to which the value is being compared.
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FIG 4 C57BL/6 mice (n ⫽ 6) were immunized two or three times, 3 weeks apart,

with 2 or 20 g of CSP1 and 50 g poly(I·C)LC. Naive mice and mice that received
poly(I·C)LC alone or 20 g of CSP1 alone served as controls. Four weeks later,
mice were challenged with 1.5 ⫻ 104 Pb-CS(Pf) sporozoites. Parasite burden was
determined 40 h postchallenge by counting the copies of 18S rRNA in the livers by
RT-PCR. Shown are comparisons of levels of protective immunity in mice that
received either two or three immunizations of 20 g CSP1 and poly(I·C)LC (A) or
three immunizations with 2 g or 20 g CSP1 and poly(I·C)LC (B). Data points
are graphed as geometrical means and are representative of two independent experiments *, P ⬍ 0.05; **, P ⬍ 0.01. The color of the asterisk (A) or the length of the
bar (B) indicates the group to which the value is being compared.

the spleens were assessed by multiparameter flow cytometry. Mice
immunized with poly(I·C)LC or any of the CSPs without adjuvant
had no measurable CSP-specific CD4⫹ T cell cytokine responses
(Fig. 2A). In contrast, 2 g of CSP1 and CSP2 administered with
poly(I·C)LC induced robust CD4⫹ T cell cytokine responses, producing IFN-␥, IL-2, and TNF-␣ (Fig. 2B). Such responses were
increased ⬃2- to 3-fold by using 20 g of CSP with poly(I·C)LC
(Fig. 2C). Remarkably, both CSPs produced in yeast (CSP3 and
CSP4) failed to induce significant antigen-specific CD4⫹ T cell
responses with poly(I·C)LC, even at the higher dose (20 g).
E. coli-derived CSP induces antibodies against the NANP repeat region. Since antibodies against CSP are critical for protection, we assessed responses against the NANP repeat region following immunization of all vaccine groups. Consistent with the
data in Fig. 2, CSP1 and CSP2 vaccines produced in E. coli elicited
significantly more potent antibody responses than did CSP3 and
CSP4 expressed in yeast (Fig. 3A to C). Higher antibody titers were
observed in mice that received the higher dose (20 g) of CSP and
poly(I·C)LC. Taken together, the E. coli-derived proteins were
more potent for CSP-specific antibody and CD4⫹ T cell immunity
in this study with poly(I·C)LC or with CpG as an adjuvant (data
not shown). Therefore, CSP1 was selected for further testing.
Protection requires three immunizations with CSP and
poly(I·C)LC. We next sought to establish the optimal antigen dose
and number of immunizations required to induce protection
against a challenge. Because mice are not susceptible to P. falciparum, we used a recombinant P. berghei parasite expressing the P.
falciparum CSP repeat region [Pb-CS(Pf)] (10) as a challenge for
our P. falciparum CSP-vaccinated mice. Mice were immunized
two or three times at 3-week intervals with 20 g of CSP1 and
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FIG 5 (A) C57BL/6 mice (n ⫽ 4 to 6) were immunized two or three times, 3
weeks apart, with 2 or 20 g of CSP1 and 50 g poly(I·C)LC. Naive mice and
mice that received poly(I·C)LC alone or 20 g of CSP1 alone served as controls. Two weeks later, sera were collected and CSP-specific IgG antibodies
were determined. Data points are graphed as means ⫹ SD. *, P ⬍ 0.05. The
values for all control groups are significantly lower than those for vaccine
groups. (B) Serum from mice immunized three times with CSP1 and
poly(I·C)LC or serum from naive mice was transferred into naive mice at the
time of challenge with 1.5 ⫻ 104 Pb-CS(Pf) sporozoites. Vaccinated mice
(CSP1 and poly(I·C)LC) served as a positive control. Forty hours postchallenge, parasite burden was determined by counting the copies of 18S rRNA in
the livers by RT-PCR. Black bars show the geometrical means. **, P ⬍ 0.01.
Results are representative of at least two independent experiments.

poly(I·C)LC. Four weeks after the last immunization, mice were
challenged i.v. with 1.5 ⫻ 104 Pb-CS(Pf) parasites. Forty hours
later, livers of infected mice were harvested and parasite-derived
18S rRNA was measured by real-time qPCR (RT-qPCR). Mice
that received two immunizations with 20 g of CSP1 and
poly(I·C)LC showed a modest but significant (⬃0.5 log) reduction (P ⬍ 0.01) of parasite-derived 18S rRNA levels compared to
naive mice or mice that received poly(I·C)LC or CSP1 alone (Fig.
4A). Moreover, three immunizations with 20 g CSP1 and
poly(I·C)LC resulted in an ⬃2- to 4-log reduction in 18S rRNA
(Fig. 4A) compared to levels in mice immunized with protein
alone, poly(I·C)LC alone, or CSP1 protein and poly(I·C)LC (two
immunizations). A separate series of experiments sought to determine whether the dose of CSP1 influenced protection. We compared three immunizations with 2 or 20 g of CSP1 and
poly(I·C)LC. As shown in Fig. 4B, the higher dose of CSP1 provided a significant (P ⫽ 0.005) (⬃2-log) reduction in parasite load
in the livers of mice compared to those with the lower dose of
CSP1. Overall, these data show that three immunizations with the
higher dose (20 g) of CSP1 and poly(I·C)LC provided significant
reduction of parasite load against a high-dose i.v. challenge with
sporozoites.
Antibody against CSP correlates with protection. In the next
series of experiments, we sought to determine the immunological
correlates of protection following immunization with CSP1 and
poly(I·C)LC. Prior studies in mice and humans showed that antibodies and CD4⫹ T cells play a role in protection (20, 22, 44–48).
In Fig. 3, we show that two immunizations with 2 or 20 g of CSP1
induced potent antibody responses against the NANP repeat region. To extend this analysis, we assessed CSP-specific antibody
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FIG 6 C57BL/6 mice (n ⫽ 6 to 18) were immunized three times, 3 weeks apart, with the indicated doses of CSP1 with either 50 g poly(I·C)LC or 5 g GLA-SE
as the adjuvant. Mice that received poly(I·C)LC, GLA-SE, or CSP1 alone, mice that received CSP1 and SE, or naive mice served as controls (not shown). CD4⫹
T cells in blood, spleen, and liver were analyzed for cytokine production by flow cytometry. (A) Frequencies of CSP-specific IFN-␥-producing CD4⫹ T cells in
the blood 7 days after the third immunization; (B, C) frequencies of CSP-specific IFN-␥-, IL-2-, TNF-␣-, or IL-10-producing CD4⫹ T cells in the spleen (B) and
liver (C) 2 weeks after three immunizations; (D) relative proportions of each individual combination of IFN-␥-, IL-2-, or TNF-␣-producing cells in the spleen
and liver 2 weeks after three immunizations. ND, not determined (because the frequency was too low). The black circle represents the percentage of CD4⫹ T cells
that make IFN-␥. Bars show the means ⫾ SD. *, P ⬍ 0.05; **, P ⬍ 0.01. All control groups had values below the limit of detection. The color of the asterisk
indicates the group to which the value is being compared. Results are representative of two independent experiments.

titers at both doses of CSP after two or three immunizations. As
shown in Fig. 5A, the greatest antibody response was detected with
the higher dose of CSP1 given three times, consistent with improved protection in this group (Fig. 4). To substantiate a direct
role of antibodies in mediating protection, pooled serum from
mice immunized three times with 20 g CSP1 and poly(I·C)LC
was transferred into naive recipients, and then the mice were challenged. As a negative control, serum from naive mice was transferred to naive mice. As a positive control, mice immunized three
times with 20 g of CSP1 and poly(I·C)LC were challenged at the
same time. Naive mice that received serum from CSP1- and
poly(I·C)LC-vaccinated animals showed an ⬃1-log reduction in
parasite burden compared to mice that received control serum or
naive mice (Fig. 5B). However, this protection was not as robust as
that seen in animals immunized with CSP1 and poly(I·C)LC. This
could be due to dilution of transferred antibodies in the blood of
recipient animals or to a contribution of vaccine-elicited CD4⫹ T
cells absent in passively transferred animals. Nevertheless, these
data show that humoral immunity is sufficient to confer some
protection against this high-dose challenge.
Poly(I·C)LC induces higher CD4ⴙ Th1 cell immunity than
GLA-SE. The RTS,S vaccine has been formulated with the TLR4
ligand MPL and QS-21 in either a liposomal solution (AS01) or
oil-in-water emulsion (AS02). Thus, to compare poly(I·C)LC
(which signals through TLR3 and MDA-5) to an adjuvant with
some commonality to AS02, we choose GLA-SE. This formulation
consists of a synthetic form of the TLR4 agonist lipid A, which has
been shown to provide adjuvant activity that is similar to, if not
better than, that of MPL-SE (49).
Mice were immunized three times with 2 g or 20 g of CSP1
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formulated with either poly(I·C)LC or GLA-SE, and the CD4⫹ T
cell responses were analyzed in the blood, spleen, and liver 7 to 14
days after the third vaccination. At this peak time point, the frequencies of IFN-␥-producing CD4⫹ T cells in the blood (Fig. 6A)
were similar when we compared the 2-g and 20-g doses of
CSP1 protein using either poly(I·C)LC or GLA-SE as an adjuvant.
However, CD4⫹ IFN-␥ responses were significantly higher when
poly(I·C)LC was used than when GLA-SE was used for both doses
of CSP1 (Fig. 6A). Moreover, in spleen (Fig. 6B) and liver (Fig.
6C), CD4⫹ T cell responses were also significantly higher using
poly(I·C)LC than using GLA-SE. Mice immunized with either adjuvant alone or CSP1 alone showed no detectable CD4⫹ T cell
responses (data not shown). Lastly, we did not detect any CD8⫹ T
cell responses (data not shown), consistent with the absence of a P.
falciparum CSP-specific CD8⫹ T cell epitope in C57BL/6 mice.
To extend this analysis, we assessed the quality of the CD4⫹ T
cell cytokine response based on the relative proportions of cells
producing IL-2, IFN-␥, and TNF-␣, either alone or simultaneously. The quality of the CD4⫹ T cell response may be an important metric because of evidence that multifunctional CD4⫹ T cells
correlate with protection (20, 23, 50). As shown in Fig. 6D, ⬃50%
of the total cytokine-producing responses were multifunctional,
producing IL-2, TNF-␣, and IFN-␥, with another ⬃25% making
IFN-␥ and TNF-␣ without IL-2. Thus, both adjuvants elicit the
induction of CD4⫹ T cells that secrete two critical effector cytokines that may mediate parasite killing (51–53).
Poly(I·C)LC and GLA-SE confer comparable levels of protection correlating with antibody titers. We next compared antibody responses induced with 2 or 20 g of CSP1 and GLA-SE to
poly(I·C)LC following three immunizations. In contrast to the
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FIG 7 C57BL/6 mice (n ⫽ 6) were immunized three times, 3 weeks apart, with the indicated doses of CSP1 together with either 50 g poly(I·C)LC or 5 g
GLA-SE. Mice that received poly(I·C)LC, GLA-SE, or CSP1 (20 g) alone or naive mice served as controls. (A) Two weeks after the third immunization, sera were
collected and CSP-specific IgG, IgG1, and IgG2a antibodies were measured. Bars are graphed as means ⫾ SD. All control groups showed significantly lower
antibody titers than the vaccine groups. (B) Four weeks after the third immunization, mice were challenged with 1.5 ⫻ 104 Pb-CS(Pf) sporozoites. Forty hours
postchallenge, parasite burden was determined by counting 18S rRNA copies in the livers by RT-PCR. Black bars show the geometrical means. The matrix (B)
represents significances among various immunization groups. *, P ⬍ 0.05; **, P ⬍ 0.01; ***, P ⬍ 0.001. (C) Correlation between antibody titers and parasite
burden in the liver. (D) Correlation between frequency of IFN-␥-producing CD4⫹ T cells in the blood (day 7) and parasite burden in the liver. (C and D) As
indicated, Pearson’s r was calculated. Results are representative of at least two independent experiments.

magnitudes of CD4⫹ T cell cytokine responses, which were significantly different, the total titers of IgG against the NANP repeats measured with the two adjuvants were not significantly
different (Fig. 7A, upper left). Of note, the lower dose (2 g) of
CSP1 consistently induced ⬃2- to 5-fold-lower total antibody
titers than the higher dose (20 g) for both adjuvants. Similar
results were seen after analyzing IgG1 and IgG2a antibody titers
(Fig. 7A). In terms of protection, there was a 2- to 3-log reduction of 18S rRNA after challenge with Pb-CS(Pf) in mice immunized with 20 g of CSP1 with poly(I·C)LC compared to
that in naive mice, consistent with the results of previous experiments (Fig. 4). Immunization with 20 g of CSP1 and
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GLA-SE resulted in similar levels of protection (Fig. 7B). Thus,
in a setting of equivalent antibody titers, there was no significant difference in protection using poly(I·C)LC or GLA-SE as
an adjuvant.
To determine whether humoral or cellular immune responses
correlated with protection, prechallenge antibody titers (Fig. 7C)
and CD4⫹ T cell cytokine responses (Fig. 7D) were plotted against
the level of protection achieved upon consecutive challenge. There
was a highly significant correlation between CSP-specific antibody
titers and the level of 18S rRNA measured in livers after parasite
challenge (Pearson r ⫽ ⫺0.7) (Fig. 7C). In contrast, there was no
correlation between the frequency of IFN-␥-producing CD4⫹ T
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TABLE 1 Antibodies in sera from mice that were immunized with a high dose of CSP1 and adjuvant showed a strong binding capacity to
sporozoites in vitro
Binding of serum antibodies to sporozoites as determined by fluorescence intensity at an antibody dilution ofa:
Vaccine

1:300

1:900

1:2,700

1:8,100

1:24,300

1:72,900

Poly(I·C)LC
GLA-SE
CSP
2 g CSP ⫹ GLA-SE
2 g CSP ⫹ poly(I·C)LC
20 g CSP ⫹ GLA-SE
20 g CSP ⫹ poly(I·C)LC

⫺
⫺
⫹
⫹⫹
⫹⫹
⫹⫹⫹
⫹⫹⫹

⫺
⫺
⫹/⫺
⫹⫹
⫹
⫹⫹
⫹⫹⫹

⫺
⫺
⫺
⫹
⫹/⫺
⫹⫹
⫹⫹

⫺
⫺
⫺
⫹
⫹/⫺
⫹
⫹

⫺
⫺
⫺
⫺
⫺
⫹
⫹

⫺
⫺
⫺
⫺
⫺
⫹/⫺
⫹/⫺

a

Serum samples that were collected 2 weeks after the third immunization (as described in the legend of Fig. 6) were pooled by group. The serum pools at different dilutions were
incubated on slides coated with fixed sporozoites. The slides were washed and incubated with a secondary fluorescently labeled antibody. Finally, slides were analyzed under a
microscope. ⫹⫹⫹, very good binding; ⫹⫹, good binding; ⫹, weak binding; ⫺, no binding. Results are representative of two independent experiments.

cells in the blood and the level protection after parasite challenge
(Pearson r ⫽ ⫺0.02) (Fig. 7D). Finally, to confirm that our vaccine-elicited CSP-specific antibodies had binding activity against
the intact parasite, we used an IFA assay to visualize direct antibody binding to sporozoites (Table 1). Consistent with the CSPspecific antibody titers, poly(I·C)LC and GLA-SE induced strong
and comparable IFA titers when they were administered with 20
g of CSP1 protein. Taken together, these data show that
poly(I·C)LC and GLA-SE differ in their capacities to induce
CD4⫹/Th1 immune responses after immunization with CSP;
however, they induce comparable antibody responses that correlate best with protection.
While reduction in parasite load in the liver following a highdose i.v. challenge may have important clinical consequences by
reducing the prepatent period and time to infection (20, 54, 55),
the most important and clearest clinical outcome is sterilizing
immunity. Thus, mice vaccinated with CSP1 and poly(I·C)LC
were i.v. challenged with a low dose of 1 ⫻ 103 Pb-CS(Pf) sporozoites and monitored daily by blood smear to establish the onset of
infection. As shown in Fig. 8, all naive mice and mice immunized
with poly(I·C)LC alone developed parasitemia within 5 days. In
contrast, 5 out of 10 mice immunized with CSP1 and poly(I·C)LC
did not develop parasitemia during the 15 days of follow-up. Also,
the prepatent period was significantly delayed (P ⬍ 0.05) in mice
that received CSP1 and poly(I·C)LC (5.8 days) compared to mice
that received poly(I·C)LC alone or naive animals (4.6 days and 4.8
days, respectively) (Fig. 8A; Table 2). Analysis of prechallenge sera
from mice vaccinated with CSP1 and poly(I·C)LC revealed that
protected mice from this group displayed significantly higher antibody titers than the nonprotected mice from this same vaccine
group (Fig. 8B). These data are consistent with human trials showing that a very high level of antibody is required for sterilizing
immunity (20, 56).
CSP and poly(I·C)LC induce humoral and cellular responses
in NHPs. Based on the results from the mouse studies, we determined whether CSP1 and poly(I·C)LC could induce potent antibody and CD4⫹ T cell responses in NHPs. NHPs are a more useful
animal model than mice for testing vaccine adjuvants because of
greater similarities to humans, with respect to innate immune
pathways and TLR expression. Rhesus macaques received either
two or three immunizations of 100 g CSP1 and poly(I·C)LC, and
CD4⫹ T cell and antibody responses were assessed at different
time points after immunization. For CD4⫹ T cell cytokine responses, a batch analysis was done on frozen PBMCs from various
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time points. As shown in Fig. S1 in the supplemental material, as
with the mouse data in Fig. 2, the frequency of CSP-specific cytokine-producing CD4⫹ T cells is increased in NHPs that received
three immunizations rather than only two immunizations (see
Fig. S1A and B in the supplemental material), with a substantial
portion of multifunctional cells secreting IFN-␥, IL-2, and TNF-␣
or IFN-␥ and TNF-␣ (Fig. S1C and D). There were also robust
CSP antibody titers that were maximal after two immunizations
with CSP1 and poly(I·C)LC. Waning antibody titers could be
boosted with a third immunization but did not exceed the levels
that were reached after two immunizations (Fig. S1E and F).
Moreover, in the IFA assay, sera from animals that received three
immunizations contained antibodies with a stronger binding ca-

FIG 8 C57BL/6 mice (n ⫽ 10 per group) were immunized three times, 3 weeks
apart, with 20 g of CSP1 together with 50 g poly(I·C)LC as the adjuvant.
Mice that received poly(I·C)LC or naive mice served as controls. (A) Five
weeks later, mice were challenged i.v. with 1 ⫻ 103 Pb-CS(Pf) sporozoites.
Starting on day 4, daily blood smears were taken and analyzed under a microscope. Kaplan-Meier plots show the time to detection of parasites in the blood
for each vaccine group after the challenge. (B) Sera collected 3 weeks before
challenge were analyzed for CSP-specific IgG antibodies. Endpoint titers are
grouped by whether mice went on to be protected from challenge. *, P ⬍ 0.05.
Results are representative of two independent experiments.
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TABLE 2 Vaccination with CSP1 and poly(I·C)LC prevents 50% of
mice from developing parasitemia after a low-dose sporozoite
challengea

Immunization

No. of
infected/no. of
challenged
mice

Prepatent
period
(days)

Protection
(%)

20 g CSP ⫹ poly(I·C)LC
Poly(I·C)LC
None (naive mice)

5/10
10/10
10/10

5.8
4.6
4.8

50
0
0

a
C57BL/6 mice (n ⫽ 10/group) were immunized three times, 3 weeks apart, with 20 g
CSP1 together with 50 g poly(I·C)LC as the adjuvant. Mice that received poly(I·C)LC
only or naive mice served as controls. Five weeks after the last immunization, mice were
challenged i.v. with 1 ⫻ 103 Pb-CS(Pf) sporozoites. Starting at day 4, daily blood smears
were taken and observed under a microscope to look for the onset of parasitemia.
Results are representative of two independent experiments.

pacity than those from animals that received two immunizations
(see Table S1 in the supplemental material). Therefore, we conclude that the CSP1 protein and poly(I·C)LC are strongly immunogenic in NHPs.
DISCUSSION

Currently, the RTS,S vaccine administered with AS01 is the most
advanced malaria vaccine, providing ⬃30 to 50% protection in
humans (2, 3). The recent results of the pivotal phase III clinical
efficacy trial were a major breakthrough in establishing that a protein/particle-based vaccine with a well-formulated adjuvant system could achieve some protective efficacy against a parasite infection and confirms this approach as a first step toward
developing a successful malaria vaccine. In the study presented
here, we compared various full-length CS proteins for their ability
to induce strong immunity and protection. Such proteins were
provided by four partners, in partnership with MVI, to enable
direct comparison and down-selection of one or more proteins for
further development, thereby providing a potentially simpler formulation than RTS,S/AS01 with comparable or improved efficacy. The data presented here using poly(I·C)LC as an adjuvant
show a striking difference between the immunogenicities elicited
by E. coli-derived CSP and yeast-derived CSP. The relatively low
responses to the yeast-derived protein were surprising, since
RTS,S (as well as other successful protein-based vaccines) is produced in yeast (57) and one of the yeast-derived proteins used in
this study when given with Montanide did elicit potent antibody
titers in mice (data not shown), showing that at least for antibody
responses, the yeast-derived protein was immunogenic. We speculate that differences in the amino acid sequences or mannosylation sites of CSPs expressed in yeast and E. coli may have accounted for the limited immunogenicity. Indeed, one of the
yeast-derived proteins induced higher antibody and CD4⫹ T cell
responses when the same amino acid sequence was expressed in E.
coli (data not shown). However, modifications in the mannosylation sites did not significantly alter the immunogenicity of yeastexpressed CSP (data not shown). Therefore, the mechanistic basis
for the differences in immunogenicity of yeast- and E. coli-expressed CSPs used in this experiment is not entirely clear. In view
of these results, CSP1 was used with the two adjuvants,
poly(I·C)LC and GLA-SE, for the remainder of the studies.
Both poly(I·C)LC and GLA-SE elicited strong and comparable
levels of CSP-specific IgG antibody titers, which conferred similar
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degrees of protection against high-dose sporozoite challenge.
However, poly(I·C)LC induced a substantially higher frequency of
CSP-specific CD4⫹ T cell cytokine responses than GLA-SE. Moreover, such responses were comprised of a large percentage of multifunctional cells secreting IFN-␥, IL-2, and TNF-␣, which have
been proposed to contribute to antimalarial protection after
RTS,S/AS01 vaccination (20, 23). Of note, while vaccination with
CSP (P. vivax) and GLA-SE in mice has been shown to induce a
robust CD4⫹ T cell effector response (58), the same vaccine induced monofunctional (IL-2 only) CD4⫹ T cell responses in
NHPs (49). In contrast, we show that CSP and poly(I·C)LC induced robust multifunctional Th1 CD4⫹ T cell responses in both
mice and NHPs. These data highlight potential differences in the
magnitudes and quality of CD4⫹ T cell responses induced in mice
and NHPs and are consistent with the results of other studies
showing poly(I·C) or poly(I·C)LC to be an especially potent adjuvant in NHPs for such responses (34, 59). Finally, it is notable that
despite the dramatic differences in the CD4⫹/Th1 responses between poly(I·C)LC and GLA-SE in mice, the antibody titers were
similar. These data highlight the possibility that adjuvants can
differentially mediate effects on antibody and Th1 immunity,
which is currently being investigated.
In terms of correlates of protection, both antibody and CD4⫹ T
cells have been described to occur in mice or humans with CSP
vaccines. Here, we show that the antibody titers using poly(I·C)LC
or GLA-SE strongly correlate with protection (Fig. 7C). Moreover,
serum transfer from CSP-immunized animals reduced the parasite burden after high-dose i.v. challenge. Thus, antibodies are
necessary and sufficient in this model. Of note, protection was best
with the higher dose of CSP (20 g), which induced an ⬃1-log
increase in antibody titer compared to that induced by the lower
dose of protein (2 g). It is notable that, in humans, 25 g or 50 g
of RTS,S induced antibody titers better than and comparable to
those induced by 10 g, suggesting some dose effect similar to
what we observed in this study (60). This suggests that there may
be a threshold for the amount of CSP-specific antibody required
to provide or increase protection. Indeed, when we analyzed antibody titers from protected and nonprotected animals (Fig. 7C
and 8B), there was a threshold for the amount of antibody required to mediate protection after low- or high-dose challenge.
This is consistent with data from humans in which anti-CSP antibody titers needed to be above 40 EU/ml (56) to induce protection. In addition, we show that nonprotected mice had a significantly delayed prepatent period compared to the control animals
(Table 2). Accordingly, studies using RTS,S and different adjuvants in humans also show that the prepatent period can be delayed. At present, it still is not clear whether this delay might play
a role in improving the clinical outcome of a malaria infection (20,
54, 55).
Regarding the role of cellular immunity in mediating protection, previous studies have shown that CD4⫹ T cells specific for P.
yoelii CSP eliminate infected hepatocytes in vitro and, when adoptively transferred, mediate protection in vivo (61, 62). The protective role of CD4⫹ effector cells against malaria was further substantiated in other murine and human malaria models (22, 63,
64). In data not shown, antibody depletion of CD4⫹ T cells in
mice immunized with CSP1 and poly(I·C)LC at the time of sporozoite challenge resulted in only modestly reduced protection.
Hence, in our model, the data support a far more critical role for
CSP antibodies in mediating protection than for CD4⫹ effector T
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cells. Nevertheless, human studies using the AS02 or AS01 adjuvant showing that improved CD4⫹ T cell responses were associated with improved protection after challenge with P. falciparum
(20, 22) provide evidence for the importance of these T cells.
Therefore, the ability of poly(I·C)LC to elicit such potent CD4⫹ T
cells in blood, liver, and spleen may be of importance in humans
through a variety of mechanisms. Indeed, IFN-␥ has been shown
to inhibit the development of liver-stage malaria in various animal
models (52, 65). That would provide a potential advantageous role
for poly(I·C)LC, based on the high frequency of those cells detected in the livers of immunized mice.
There is also strong evidence for cytotoxic CD8⫹ T cells in
mediating protective immunity against liver-stage malaria (18, 46,
66, 67). As our study used a strain of mice in which there was no
major histocompatibility complex (MHC) class I recognition of P.
falciparum CSP peptides, we did not detect any CD8⫹ T cell responses. However, we and others have previously shown that type
I IFN is essential for mediating cross-priming of protein in mice
(68, 69), highlighting the potential advantage of poly(I·C)LC over
other adjuvants (25). Nevertheless, while adjuvants that induce
type I IFN should be preferred to induce CD8⫹ T cell responses
upon protein vaccination, virus-based vaccines seem preferable if
robust CD8⫹ T cell immunity is required. Improving how the
protein is formulated and targeting it to specific dendritic cell
subsets may ultimately improve the capacity of such vaccines to
consistently and efficiently induce CD8⫹ T cells.
In conclusion, we show that a full-length P. falciparum CS protein when combined with poly(I·C)LC or GLA-SE induces potent
immunity and protection in mice. Moreover, poly(I·C)LC is an
effective adjuvant for eliciting such responses in NHPs, providing
a predictive model for what might occur in humans (20, 21, 70,
71). It is possible that the increased breadth of CSP responses with
a full-length CSP (compared to the CSP responses with truncated
RTS,S) and/or the enhanced CD4⫹ Th1 immunity that would
potentially be elicited by poly(I·C)LC would enhance protection
and/or durability. Whether a full-length protein vaccine with an
adjuvant would substantially improve the outcome over the current platforms of RTS,S/AS01 and RTS,S/AS02, which have the
advantages of being particles with well-formulated adjuvants and
of being safe and scalable, remains a question for further development. Our study shows that a protein platform can provide effective protection against malaria. The key question for future studies
is whether this protection will also provide a prolonged durability
compared to that of the RTS,S vaccine.
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Supplementary Figure 1:
Rhesus macaques were immunized with 100µg of CSP1 protein mixed with
1mg of poly-ICLC. A total volume of 1ml was injected s.c. in the deltoid
area of the upper arm. For boosting, the opposite arm was used. NHPs were
immunized at weeks 0, 5 and 16. At indicated time-points after
immunizations blood was collected and PBMCs were used for stimulation
for ICS. Serum was also collected at indicated time-points to determine
antibody titers. Frequency of CSP-specific IFN-γ-, IL-2- or TNFαproducing CD4+ T cells in PBMCs collected at peak (two weeks) and
memory (15 weeks) after two (A) or three (B) immunizations. Relative
proportion of each individual combination of IFN-γ-, IL-2-, or TNFαproducing cells in PBMCs collected at peak (two weeks) and memory (15
weeks) after two (C) or three (D) immunizations. (E and F) CSP-specific
IgG antibody titers.
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Supplementary Table 1: Antibodies in serum from monkeys that received three
immunizations with CSP1 and poly-ICLC adjuvant showed a strong binding
capacity to sporozoites in vitro. Serum was collected at indicated time-points and
IFA was performed as described in Table 1. +++ very good binding, ++ good binding,
+ weak binding, - no binding.
	
  
	
  
	
  
	
  

